Cargando…
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
The aim of this study was to investigate long-term outcome following first-line therapy in consecutive chronic lymphocytic leukemia (CLL) patients in a well-defined geographic area: Sweden. All patients diagnosed with CLL (2007–2013) (n=3672) were identified from national registries, screening of pa...
Autores principales: | Sylvan, Sandra Eketorp, Asklid, Anna, Johansson, Hemming, Klintman, Jenny, Bjellvi, Jenny, Tolvgård, Staffan, Kimby, Eva, Norin, Stefan, Andersson, Per-Ola, Karlsson, Claes, Karlsson, Karin, Lauri, Birgitta, Mattsson, Mattias, Sandstedt, Anna Bergendahl, Strandberg, Maria, Österborg, Anders, Hansson, Lotta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442960/ https://www.ncbi.nlm.nih.gov/pubmed/30467205 http://dx.doi.org/10.3324/haematol.2018.200204 |
Ejemplares similares
-
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
por: Hansson, Lotta, et al.
Publicado: (2017) -
Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients
por: Mattsson, Agnes, et al.
Publicado: (2020) -
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
por: Sylvan, S Eketorp, et al.
Publicado: (2014) -
Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016) -
PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL-DEFINED REGION.
por: Andersson, Maria, et al.
Publicado: (2023)